Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recen...( - 2008 revenue expected to grow t...)

- 2008 revenue expected to grow to $160 million or more, up from $42

million in 2007 -

- First HGS product sales expected with delivery of ABthrax(TM) to

Strategic National Stockpile -

- First Albuferon(R) Phase 3 data expected late 2008 - - Enrollment completed in randomized Phase 2 trial of HGS-ETR1 in multiple

myeloma -

ROCKVILLE, Md., Feb. 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter and full year ended December 31, 2007, and provided highlights of recent progress toward commercialization.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"2007 was a year of execution for HGS, during which we delivered substantial progress toward the commercialization of our late-stage products. We are poised to achieve a number of major milestones in 2008 across our entire portfolio," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We expect our first product sales later this year when we begin to deliver ABthrax to the U.S. Strategic National Stockpile, and our cash position remains strong. We expect to have our first Phase 3 data for Albuferon late this year, and we will complete enrollment in the Phase 3 trials of LymphoStat-B(R) by fall 2008. We also believe it is possible that GSK will reach decisions in 2008 regarding whether to advance darapladib and Syncria to Phase 3 development."

FINANCIAL RESULTS: CASH POSITION REMAINS STRONG

HGS reported increased revenues of $41.9 million for the year ended December 31, 20
'/>"/>